Quick Answer
Jaguar Health, Inc. reported Total Revenue of $11.69 million for fiscal year 2024.
Jaguar Health, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $11.69M +19.8% |
$9.76M -18.4% |
$11.96M +175.8% |
$4.33M -53.8% |
$9.38M +62.5% |
$5.78M +30.8% |
| Net Income | -$38.49M +6.8% |
-$41.30M +13.0% |
-$47.45M | — | -$33.81M +12.3% |
-$38.54M -19.9% |
| Diluted EPS | -$130.69 +95.1% |
-$2678.17 -7302.3% |
-$36.18 +59.0% |
-$88.22 -2840.7% |
-$3.00 | — |
| Total Assets | $53.42M +5.2% |
$50.76M +7.0% |
$47.45M -10.9% |
$53.27M +24.3% |
$42.84M +17.7% |
$36.41M -11.3% |
| Cash and Equivalents | $8.00M +23.7% |
$6.47M +18.3% |
$5.47M -67.9% |
$17.05M +110.8% |
$8.09M +131.5% |
$3.50M +36.1% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $6.49M +32.6% |
$4.90M +460.3% |
-$1.36M -111.5% |
$11.85M -31.1% |
$17.20M +61.2% |
$10.67M +98.3% |
| R&D Expense | $16.54M -11.0% |
$18.60M +5.4% |
$17.65M +17.0% |
$15.08M +135.1% |
$6.41M +10.2% |
$5.82M +12.9% |
| Operating Income | -$30.83M +10.1% |
-$34.29M +0.4% |
-$34.41M +15.5% |
-$40.71M -52.8% |
-$26.65M +7.9% |
-$28.95M +6.1% |
| Shares Outstanding | — | — | — | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $3.08M | -0.8% | +3.5% |
| Net Income | September 30, 2025 | -$9.50M | +3.6% | +8.7% |
| Diluted EPS | September 30, 2025 | -$6.28 | +76.1% | +38.8% |
| Total Assets | September 30, 2025 | $49.47M | -15.4% | +2.5% |
| Cash and Equivalents | September 30, 2025 | $3.53M | -73.4% | +59.8% |
| Long-Term Debt | June 30, 2018 | $10.77M | +1188.1% | -1.0% |
| Stockholders Equity | September 30, 2025 | $4.36M | -66.7% | -36.6% |
| R&D Expense | September 30, 2025 | $3.66M | -9.5% | +12.0% |
| Operating Income | September 30, 2025 | -$7.24M | +0.3% | +9.6% |
| Shares Outstanding | June 30, 2017 | 17.48M | +61.6% | +21.2% |
- Jaguar Health, Inc. reported Total Revenue of $11.69 million for fiscal year 2024.
- Jaguar Health, Inc. showed an increase of +19.8% in Total Revenue compared to the prior fiscal year.
- Jaguar Health, Inc. reported Net Income of -$38.49 million for fiscal year 2024.
- Jaguar Health, Inc. showed an increase of +6.8% in Net Income compared to the prior fiscal year.
- Jaguar Health, Inc. reported Diluted EPS of $130.69 per share (loss) for fiscal year 2024.
- Jaguar Health, Inc. showed an increase of +95.1% in Diluted EPS compared to the prior fiscal year.
- Jaguar Health, Inc. reported Total Assets of $53.42 million for fiscal year 2024.
- Jaguar Health, Inc. showed an increase of +5.2% in Total Assets compared to the prior fiscal year.
- Jaguar Health, Inc. reported Cash and Equivalents of $8.00 million for fiscal year 2024.
- Jaguar Health, Inc. showed an increase of +23.7% in Cash and Equivalents compared to the prior fiscal year.
- Jaguar Health, Inc. reported Long-Term Debt of $1.82 million for fiscal year 2016.
- Jaguar Health, Inc. showed a decrease of -55.6% in Long-Term Debt compared to the prior fiscal year.
- Jaguar Health, Inc. reported Stockholders Equity of $6.49 million for fiscal year 2024.
- Jaguar Health, Inc. showed an increase of +32.6% in Stockholders Equity compared to the prior fiscal year.
- Jaguar Health, Inc. reported R&D Expense of $16.54 million for fiscal year 2024.
- Jaguar Health, Inc. showed a decrease of -11.0% in R&D Expense compared to the prior fiscal year.
- Jaguar Health, Inc. reported Operating Income of -$30.83 million for fiscal year 2024.
- Jaguar Health, Inc. showed an increase of +10.1% in Operating Income compared to the prior fiscal year.
- Jaguar Health, Inc. reported Shares Outstanding of 14.01 million shares for fiscal year 2016.
- Jaguar Health, Inc. showed an increase of +72.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: